En vivo

PharmaVoiceFormer Ovid CEO Dr. Jeremy Levin’s rallying cry for biotech Endpoints NewsM&A isn’t just for big pharma. Mid-size companies are stepping up deal hunts LabiotechCAR-T therapy for stiff person syndrome nears approval Endpoints NewsAndrea Pfeifer ends 23-year reign at AC Immune; Acadia's top R&D exec announces retirement Endpoints News#ASGCT26: A Zillow-like marketplace for abandoned gene therapies goes live FierceBiotechAlumis pulls back from would-be rival to Amgen’s Tepezza after assessing prospects LabiotechFreeze variability, not progress: strengthen your cell therapy supply chain from the start Endpoints NewsSupreme Court preserves mail access for abortion pill FierceBiotechAardvark to dig into phase 3 data early after FDA imposes hold Siemens HealthineersSiemens Healthineers Wins Key US Clearances As Valuation Gap Widens - simplywall.st BioNTechBioNTech’s Clinical and Corporate Overhaul: Cancer Data Improves as COVID Era Ends - AD HOC NEWS Every GreenBiotech Just Hit Fast Forward. Is Europe’s Seed Sector Ready? - seedworld.com

Labiotech 15 may 2026

Freeze variability, not progress: strengthen your cell therapy supply chain from the start

Our guest today is Dominic Clark, Vice President of Technical Operations for IntegriCell at Cryoport Systems. The post Freeze variability, not progress: strengt...

Our guest today is Dominic Clark, Vice President of Technical Operations for IntegriCell at Cryoport Systems. The post Freeze variability, not progress: strengthen your cell therapy supply chain from the start appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.